Logo image of ZLAB

ZAI LAB LTD-ADR (ZLAB) Stock Fundamental Analysis

NASDAQ:ZLAB - US98887Q1040 - ADR

32.22 USD
-0.34 (-1.04%)
Last: 8/28/2025, 8:00:02 PM
32.22 USD
0 (0%)
After Hours: 8/28/2025, 8:00:02 PM
Fundamental Rating

4

Overall ZLAB gets a fundamental rating of 4 out of 10. We evaluated ZLAB against 547 industry peers in the Biotechnology industry. ZLAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ZLAB is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ZLAB had negative earnings in the past year.
ZLAB had a negative operating cash flow in the past year.
ZLAB had negative earnings in each of the past 5 years.
ZLAB had a negative operating cash flow in each of the past 5 years.
ZLAB Yearly Net Income VS EBIT VS OCF VS FCFZLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

With a decent Return On Assets value of -18.26%, ZLAB is doing good in the industry, outperforming 78.79% of the companies in the same industry.
ZLAB has a better Return On Equity (-26.84%) than 80.07% of its industry peers.
Industry RankSector Rank
ROA -18.26%
ROE -26.84%
ROIC N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ZLAB Yearly ROA, ROE, ROICZLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Gross Margin of ZLAB (62.46%) is better than 79.16% of its industry peers.
In the last couple of years the Gross Margin of ZLAB has declined.
ZLAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
ZLAB Yearly Profit, Operating, Gross MarginsZLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K

More info and screens

4

2. Health

2.1 Basic Checks

ZLAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZLAB has more shares outstanding
ZLAB has more shares outstanding than it did 5 years ago.
ZLAB has a worse debt/assets ratio than last year.
ZLAB Yearly Shares OutstandingZLAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ZLAB Yearly Total Debt VS Total AssetsZLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

ZLAB has an Altman-Z score of 3.17. This indicates that ZLAB is financially healthy and has little risk of bankruptcy at the moment.
ZLAB has a Altman-Z score of 3.17. This is in the better half of the industry: ZLAB outperforms 73.31% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that ZLAB is not too dependend on debt financing.
ZLAB's Debt to Equity ratio of 0.22 is on the low side compared to the rest of the industry. ZLAB is outperformed by 68.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 3.17
ROIC/WACCN/A
WACC8.33%
ZLAB Yearly LT Debt VS Equity VS FCFZLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 3.12 indicates that ZLAB has no problem at all paying its short term obligations.
ZLAB's Current ratio of 3.12 is on the low side compared to the rest of the industry. ZLAB is outperformed by 62.89% of its industry peers.
A Quick Ratio of 2.93 indicates that ZLAB has no problem at all paying its short term obligations.
ZLAB's Quick ratio of 2.93 is on the low side compared to the rest of the industry. ZLAB is outperformed by 62.34% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.93
ZLAB Yearly Current Assets VS Current LiabilitesZLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

ZLAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
ZLAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.56%.
Measured over the past years, ZLAB shows a very strong growth in Revenue. The Revenue has been growing by 98.34% on average per year.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)32.56%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%9.43%

3.2 Future

Based on estimates for the next years, ZLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 89.06% on average per year.
Based on estimates for the next years, ZLAB will show a very strong growth in Revenue. The Revenue will grow by 41.74% on average per year.
EPS Next Y43.7%
EPS Next 2Y50.17%
EPS Next 3Y58.73%
EPS Next 5Y89.06%
Revenue Next Year43.83%
Revenue Next 2Y49.37%
Revenue Next 3Y48.21%
Revenue Next 5Y41.74%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ZLAB Yearly Revenue VS EstimatesZLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
ZLAB Yearly EPS VS EstimatesZLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZLAB. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 51.50, the valuation of ZLAB can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ZLAB indicates a rather cheap valuation: ZLAB is cheaper than 89.95% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.78. ZLAB is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 51.5
ZLAB Price Earnings VS Forward Price EarningsZLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLAB Per share dataZLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZLAB's earnings are expected to grow with 58.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.17%
EPS Next 3Y58.73%

More info and screens

0

5. Dividend

5.1 Amount

ZLAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZAI LAB LTD-ADR

NASDAQ:ZLAB (8/28/2025, 8:00:02 PM)

After market: 32.22 0 (0%)

32.22

-0.34 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/dmh
Earnings (Next)11-10 2025-11-10
Inst Owners45.81%
Inst Owner Change-24.68%
Ins Owners1.3%
Ins Owner Change6.85%
Market Cap3.59B
Analysts78.46
Price Target35.85 (11.27%)
Short Float %4.41%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)15.62%
Min EPS beat(4)-12.04%
Max EPS beat(4)50.98%
EPS beat(8)6
Avg EPS beat(8)16.58%
EPS beat(12)9
Avg EPS beat(12)32.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.38%
Min Revenue beat(2)-14.17%
Max Revenue beat(2)-10.58%
Revenue beat(4)0
Avg Revenue beat(4)-7.13%
Min Revenue beat(4)-14.17%
Max Revenue beat(4)-1.65%
Revenue beat(8)3
Avg Revenue beat(8)-2.39%
Revenue beat(12)5
Avg Revenue beat(12)-2.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.04%
PT rev (3m)7.62%
EPS NQ rev (1m)-0.23%
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.14%
EPS NY rev (3m)4.79%
Revenue NQ rev (1m)-9.27%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.01%
Revenue NY rev (3m)-1.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 51.5
P/S 8.38
P/FCF N/A
P/OCF N/A
P/B 4.53
P/tB 4.9
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)0.63
Fwd EY1.94%
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS3.84
BVpS7.12
TBVpS6.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.26%
ROE -26.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.46%
FCFM N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 425.16%
Cap/Sales 13.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.12
Quick Ratio 2.93
Altman-Z 3.17
F-Score4
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)305.55%
Cap/Depr(5y)287.72%
Cap/Sales(3y)10.07%
Cap/Sales(5y)13.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y43.7%
EPS Next 2Y50.17%
EPS Next 3Y58.73%
EPS Next 5Y89.06%
Revenue 1Y (TTM)32.56%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%9.43%
Revenue Next Year43.83%
Revenue Next 2Y49.37%
Revenue Next 3Y48.21%
Revenue Next 5Y41.74%
EBIT growth 1Y30.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.05%
EBIT Next 3Y36.62%
EBIT Next 5Y32.27%
FCF growth 1Y39.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.78%
OCF growth 3YN/A
OCF growth 5YN/A